In the treatment of neuroendocrine tumors (NETs), somatostatin analogs (SSAs) are synthetic derivatives of the somatostatin hormone. These medications have the potential to suppress tumor growth in somatostatin receptor-positive tumors and to slow down or halt tumor progression in metastatic neuroendocrine cancers. They also effectively control symptoms caused by hormones secreted by tumors (e.g., flushing, diarrhea, and wheezing in carcinoid syndrome). Particularly in patients with carcinoid tumors, SSAs like octreotide can be used prophylactically or therapeutically to prevent and manage complications arising from the release of serotonin and other vasoactive hormones during surgical procedures.